WIN2 Antibody

What is WIPI2 and what cellular processes does it regulate?

WIPI2 (WD repeat domain phosphoinositide-interacting protein 2) functions as a critical component of the cellular autophagy machinery. It plays an essential role in the major intracellular degradation process by which cytoplasmic materials are packaged into autophagosomes and delivered to lysosomes for degradation. WIPI2 is specifically involved in an early step of preautophagosomal structure formation, where it binds and is activated by phosphatidylinositol 3-phosphate (PtdIns3P) that forms on endoplasmic reticulum membranes following activation of upstream ULK1 and PI3 kinases. This binding event represents one of the initiating steps in the autophagy cascade. Once activated, WIPI2 mediates ER-isolation membrane contacts through interactions with the ULK1:RB1CC1 complex, serving as a crucial bridge in membrane dynamics during autophagosome formation .

What are the main applications for WIPI2 antibodies in autophagy research?

WIPI2 antibodies serve as valuable tools for investigating various aspects of autophagy in laboratory settings. The primary applications include: Western blotting (WB) for quantitative assessment of WIPI2 expression levels; Immunohistochemistry (IHC-P) for visualizing WIPI2 localization in tissue sections; Immunocytochemistry/Immunofluorescence (ICC/IF) for subcellular localization studies, particularly for tracking the recruitment of WIPI2 to preautophagosomal structures; and flow cytometry (Flow Cyt) for quantifying WIPI2 expression in individual cells within heterogeneous populations. These applications collectively enable researchers to track autophagy initiation, progression, and regulation in various experimental contexts. WIPI2 antibodies are particularly useful for visualizing early autophagosome formation sites, as WIPI2 puncta formation represents a reliable marker for autophagy induction that precedes LC3 lipidation .

How does WIPI2 interact with other autophagy-related proteins?

WIPI2 functions within a complex network of protein interactions during autophagosome formation. After being activated by PtdIns3P on membranes of the endoplasmic reticulum, WIPI2 recruits the ATG12-ATG5-ATG16L1 complex to phagophore assembly sites. This recruitment is crucial for the subsequent steps of autophagosomal membrane elongation. WIPI2 (particularly isoform 4) also mediates the recruitment of this complex to omegasomes and preautophagosomal structures, which results in ATG8 family proteins lipidation. Additionally, WIPI2 interacts with the ULK1:RB1CC1 complex at ER-isolation membrane contact sites, serving as an important bridge between membrane dynamics and protein recruitment. In the context of bacterial invasion, isoform 4 of WIPI2 binds to membranes surrounding pathogens like Salmonella and recruits the ATG12-5-16L1 complex, initiating LC3 conjugation, autophagosomal membrane formation, and pathogen engulfment .

How do different WIPI2 isoforms contribute to distinct autophagy pathways?

WIPI2 exists in multiple isoforms with specialized functions in autophagy regulation. Isoform 4, in particular, plays critical roles in both starvation-induced autophagy and selective autophagy targeting pathogens. In starvation-induced autophagy, isoform 4 recruits the ATG12-ATG5-ATG16L1 complex to omegasomes and preautophagosomal structures, facilitating ATG8 family proteins lipidation. This isoform is also specifically required for autophagic clearance of pathogenic bacteria. When bacterial pathogens like Salmonella invade cells, WIPI2 isoform 4 binds to the membrane surrounding the bacteria and recruits the ATG12-5-16L1 complex. This interaction initiates LC3 conjugation, leading to autophagosomal membrane formation and bacterial engulfment. The distinct functional roles of different WIPI2 isoforms highlight the complexity and specificity of autophagy regulation in response to different cellular stresses and pathogenic challenges .

What are the current challenges in generating highly specific WIPI2 antibodies for distinguishing between closely related proteins?

Generating highly specific antibodies that can distinguish between WIPI2 and other closely related WIPI family proteins (WIPI1, WIPI3, and WIPI4) represents a significant technical challenge in autophagy research. This challenge stems from the considerable sequence homology between these family members. Recent advances in de novo antibody design technologies offer promising approaches to address this specificity issue. Contemporary computational methods can achieve high molecular specificity through precision molecular design based on atomic-accuracy structure prediction. These methods have demonstrated the capability to generate antibodies that can distinguish closely related protein subtypes or mutants. The challenge requires careful epitope selection, focusing on regions that are unique to WIPI2 but accessible for antibody binding. Validation of such antibodies necessitates rigorous testing against all WIPI family members to confirm specificity, often requiring knockout cell lines for each family member to ensure absolute specificity in experimental applications .

How can structural information about WIPI2 inform epitope selection for antibody generation?

Understanding the three-dimensional structure of WIPI2 provides crucial insights for rational epitope selection in antibody generation. WIPI2 contains WD40 repeats that form a β-propeller structure, which is essential for its interaction with phosphoinositides and protein partners. When designing antibodies against WIPI2, researchers should consider selecting epitopes that are: (1) Surface-exposed to ensure accessibility for antibody binding; (2) Unique to WIPI2 compared to other WIPI family members to ensure specificity; (3) Not involved in critical protein-protein or protein-lipid interactions if the goal is to detect rather than disrupt WIPI2 function; and (4) Structurally stable across different conformational states of the protein. Advanced computational antibody design approaches now allow for precision targeting of specific epitopes through atomic-accuracy structure prediction. These approaches can generate binders with varying strengths for specific targets, even without prior antibody information, by creating libraries of approximately 10^6 sequences that combine designed light and heavy chain sequences in various combinations .

What is the recommended protocol for detecting endogenous WIPI2 in Western blotting?

For effective detection of endogenous WIPI2 by Western blotting, the following optimized protocol is recommended: (1) Sample preparation: Lyse cells in RIPA buffer supplemented with protease inhibitors, sonicate briefly, and centrifuge to remove debris; (2) Protein separation: Load 20-40 μg of total protein per lane on a 10-12% SDS-PAGE gel; (3) Transfer: Use a PVDF membrane for protein transfer, as WIPI2 (approximately 49 kDa) transfers efficiently to this membrane type; (4) Blocking: Block the membrane with 5% non-fat dry milk in TBST for 1 hour at room temperature; (5) Primary antibody incubation: Dilute anti-WIPI2 antibody [2A2] at 1:1000 in blocking solution and incubate overnight at 4°C; (6) Secondary antibody: Use HRP-conjugated anti-mouse secondary antibody at 1:5000 dilution for 1 hour at room temperature; (7) Development: Visualize using enhanced chemiluminescence detection. For autophagy studies, it's advisable to run samples from cells under both basal and autophagy-induced conditions (e.g., starvation or rapamycin treatment) as controls. When interpreting results, be aware that WIPI2 has multiple isoforms that may appear as distinct bands, with isoform 4 being particularly important for autophagy regulation .

How can flow cytometry be optimized for intracellular WIPI2 detection?

Optimizing flow cytometry for intracellular WIPI2 detection requires careful attention to fixation, permeabilization, and antibody titration. The recommended protocol includes: (1) Cell preparation: Harvest 1×10^6 cells per sample, wash with PBS, and fix with 4% paraformaldehyde for 15 minutes at room temperature; (2) Permeabilization: Use a saponin-based permeabilization buffer (0.1% saponin in PBS with 0.5% BSA) which allows antibody access while maintaining cellular integrity; (3) Blocking: Incubate cells in permeabilization buffer containing 2% normal serum for 30 minutes; (4) Primary antibody: Dilute anti-WIPI2 antibody [2A2] at 1:100 to 1:500 in permeabilization buffer and incubate for 45-60 minutes at room temperature; (5) Washing: Wash twice with permeabilization buffer; (6) Secondary antibody: If using unconjugated primary antibody, incubate with fluorophore-conjugated secondary antibody at appropriate dilution for 30-45 minutes; (7) Final wash: Wash twice and resuspend in flow cytometry buffer for analysis. When performing multiparameter analysis, include appropriate compensation controls and consider using a fixable viability dye to exclude dead cells. For autophagy studies, parallel samples with autophagy inducers and inhibitors provide valuable positive and negative controls for validating WIPI2 staining specificity .

How can researchers distinguish between specific and non-specific WIPI2 antibody binding in their experiments?

Distinguishing specific from non-specific WIPI2 antibody binding requires implementation of appropriate controls and validation strategies. First, researchers should include a negative control by using WIPI2 knockout or knockdown cells, which should show significantly reduced or absent signal compared to wild-type cells. Second, using multiple antibodies targeting different WIPI2 epitopes can help confirm specificity - concordant results strengthen confidence in specific binding. Third, peptide competition assays, where the antibody is pre-incubated with excess WIPI2 peptide corresponding to the epitope, should abolish specific binding signals. Fourth, for immunofluorescence studies, co-localization with known WIPI2 interaction partners (like ATG12-ATG5-ATG16L1 complex components) under autophagy-inducing conditions provides functional validation. Fifth, antibody titration experiments should show signal reduction with decreasing antibody concentration in a predictable manner. Finally, cross-reactivity testing against other WIPI family proteins (WIPI1, WIPI3, WIPI4) is crucial to ensure the antibody specifically recognizes WIPI2. Implementing these validation approaches is essential for generating reliable and reproducible data in WIPI2 research .

What are potential causes for variability in WIPI2 puncta quantification across different cell types?

Variability in WIPI2 puncta quantification across different cell types stems from multiple biological and technical factors that researchers must consider when designing experiments and interpreting results. At the biological level, different cell types exhibit varying baseline autophagy levels and WIPI2 expression, with some cell types showing constitutively higher autophagy flux than others. Cell-type specific expression of WIPI2 isoforms may also contribute to differences, as isoform 4 is particularly important for autophagy regulation. The cellular metabolic state significantly impacts autophagy induction thresholds, with nutrient-sensitive cells showing more robust responses to starvation. At the technical level, cell confluence and growth conditions directly affect baseline autophagy, requiring standardization for comparative studies. Fixation methods differentially preserve WIPI2 puncta, with methanol fixation often superior for puncta visualization compared to paraformaldehyde. Antibody penetration efficiency varies between cell types with different membrane compositions and sizes. To minimize these variables, researchers should: standardize cell culture conditions, calibrate starvation duration for each cell type, use internal controls, employ automated image analysis algorithms for unbiased quantification, and validate findings with complementary autophagy assays .

How can computational antibody design approaches be applied to develop next-generation WIPI2 antibodies?

Recent advances in computational antibody design offer promising approaches for developing next-generation WIPI2 antibodies with enhanced specificity and functionality. De novo antibody design can now be achieved through precision molecular design based on atomic-accuracy structure prediction, without requiring prior antibody information. This approach involves generating approximately 10^6 candidate sequences by combining designed light chain sequences (approximately 10^2) with heavy chain sequences (approximately 10^4). The process begins with selecting key binding sites (epitopes) on WIPI2, consisting of two to five residues that define the desired binding region. Computational methods then generate target-binding antibody structures and sequences, which can be screened through yeast display libraries. Recent studies have demonstrated successful binder identification across multiple target proteins, including cases where no experimentally resolved target protein structure was available. Importantly, this approach has produced antibodies capable of distinguishing closely related protein subtypes or mutants, which would be particularly valuable for differentiating WIPI2 from other WIPI family members. Furthermore, antibodies generated through this method have shown comparable affinity, activity, and developability to commercial antibodies, highlighting the potential for creating WIPI2-specific antibodies with tailored properties for research and therapeutic applications .

What are the emerging applications of WIPI2 antibodies in studying selective autophagy pathways?

WIPI2 antibodies are increasingly being employed to investigate selective autophagy pathways that target specific cellular components or invading pathogens. In xenophagy (the selective autophagy of intracellular pathogens), WIPI2 antibodies help visualize how WIPI2 isoform 4 specifically binds to membranes surrounding pathogens like Salmonella and recruits the ATG12-5-16L1 complex. This recruitment initiates LC3 conjugation, autophagosomal membrane formation, and pathogen engulfment. By combining WIPI2 antibodies with pathogen-specific markers and other autophagy proteins in multi-color imaging, researchers can track the temporal dynamics of pathogen recognition and isolation. In mitophagy (selective autophagy of mitochondria), WIPI2 antibodies aid in understanding how damaged mitochondria are targeted for degradation, particularly the early recognition events that precede mitochondrial engulfment. For studying aggrephagy (clearance of protein aggregates), WIPI2 immunostaining helps determine whether standard or specialized autophagy machinery is involved in aggregate clearance. These emerging applications are enhanced by super-resolution microscopy techniques that allow precise spatial localization of WIPI2 relative to cargo and other autophagy proteins, providing unprecedented insights into the mechanics of selective cargo recognition .

How might single-cell analysis using WIPI2 antibodies advance our understanding of autophagy heterogeneity in complex tissues?

Single-cell analysis using WIPI2 antibodies offers a powerful approach to uncover the heterogeneity of autophagy regulation within complex tissues, potentially revealing cell-specific responses that are masked in bulk analyses. Flow cytometry combined with intracellular WIPI2 staining enables quantification of autophagy activation across thousands of individual cells, allowing researchers to identify distinct cellular subpopulations with varying autophagy responses within the same tissue. This approach can be enhanced by simultaneous measurement of multiple autophagy markers (WIPI2, LC3, p62) and cell type-specific markers, creating high-dimensional data sets that reveal cell type-specific autophagy signatures. When applied to tissue sections, multiplex immunofluorescence incorporating WIPI2 antibodies allows spatial mapping of autophagy activation in relation to tissue architecture and microenvironmental factors. Single-cell technologies can also track autophagy dynamics in response to stressors or disease progression across diverse cell populations within a tissue. These approaches are particularly valuable in heterogeneous contexts like tumors, where cancer cells, stromal cells, and immune cells may exhibit dramatically different autophagy responses that impact disease progression and treatment response. By revealing this heterogeneity, single-cell WIPI2 analysis could identify specific cellular populations for therapeutic targeting and provide insights into the cell-specific roles of autophagy in tissue homeostasis and disease .

WIPI2 Antibody Performance Across Research Applications

This performance data is based on validated applications reported for mouse monoclonal anti-WIPI2 antibodies [2A2] across multiple experimental platforms .

Troubleshooting Guide for Common WIPI2 Antibody Application Issues

This troubleshooting guide addresses common challenges researchers face when working with WIPI2 antibodies across different experimental platforms, with practical solutions based on established protocols .